Company intelligence / Profile preview

LAVA Therapeutics

Utrecht, Utrecht, Netherlandslavatherapeutics.com ↗
Ownership
Public · LVTX
Employees
~50
Development stage
Phase 1
01

Overview

Currently conducting Phase 1/2a clinical trials for lead candidates LAVA-051 and LAVA-1207

Therapeutic areas
Oncology
Modalities
Bispecific gamma-delta T cell engaging antibodies (gamma-delta bsTCEs)
Industry
Biotech
02

Drug pipeline

4 assets

CD1d-NKT bispecific antibody

Unknown

3 more assets in the full pipeline.

Beyond the preview

Go deeper on LAVA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAVA Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call